BioNTech Management
Management criteria checks 4/4
BioNTech's CEO is Ugur Sahin, appointed in Jan 2008, has a tenure of 16.92 years. total yearly compensation is €3.06M, comprised of 22.9% salary and 77.1% bonuses, including company stock and options. directly owns 17.23% of the company’s shares, worth $4.91B. The average tenure of the management team and the board of directors is 3.4 years and 4.7 years respectively.
Key information
Ugur Sahin
Chief executive officer
€3.1m
Total compensation
CEO salary percentage | 22.9% |
CEO tenure | 16.9yrs |
CEO ownership | 17.2% |
Management average tenure | 3.4yrs |
Board average tenure | 4.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -€467m |
Jun 30 2024 | n/a | n/a | -€504m |
Mar 31 2024 | n/a | n/a | €113m |
Dec 31 2023 | €3m | €700k | €930m |
Sep 30 2023 | n/a | n/a | €3b |
Jun 30 2023 | n/a | n/a | €4b |
Mar 31 2023 | n/a | n/a | €6b |
Dec 31 2022 | €6m | €360k | €9b |
Sep 30 2022 | n/a | n/a | €10b |
Jun 30 2022 | n/a | n/a | €12b |
Mar 31 2022 | n/a | n/a | €13b |
Dec 31 2021 | €12m | €360k | €10b |
Sep 30 2021 | n/a | n/a | €7b |
Jun 30 2021 | n/a | n/a | €4b |
Mar 31 2021 | n/a | n/a | €1b |
Dec 31 2020 | €17m | €360k | €15m |
Sep 30 2020 | n/a | n/a | -€410m |
Jun 30 2020 | n/a | n/a | -€230m |
Mar 31 2020 | n/a | n/a | -€192m |
Dec 31 2019 | €7m | €311k | -€179m |
Sep 30 2019 | n/a | n/a | -€122m |
Jun 30 2019 | n/a | n/a | -€116m |
Mar 31 2019 | n/a | n/a | -€77m |
Dec 31 2018 | €653k | €210k | -€48m |
Compensation vs Market: Ugur's total compensation ($USD3.23M) is below average for companies of similar size in the UK market ($USD5.85M).
Compensation vs Earnings: Ugur's compensation has been consistent with company performance over the past year.
CEO
Ugur Sahin (59 yo)
16.9yrs
Tenure
€3,056,000
Compensation
Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 16.9yrs | €3.06m | 17.23% $ 5.0b | |
Co-Founder | 6.9yrs | €814.00k | 0.38% $ 111.2m | |
CFO & Member of Management Board | 3.4yrs | €1.32m | 0.00068% $ 198.4k | |
MD, COO & Member of Management Board | 10.9yrs | €821.00k | 0.31% $ 91.9m | |
Chief Strategy Officer | 4.9yrs | €1.41m | 0.0061% $ 1.8m | |
Chief Legal & Business Officer & Member of the Management Board | 1.3yrs | €848.00k | no data | |
Executive Officer | less than a year | €133.00k | 0.34% $ 99.2m | |
Senior Vice President of Global Financial Reporting & Accounting | less than a year | no data | no data | |
Senior Vice President of Corporate Development & Strategy | less than a year | no data | no data | |
Senior VP & External Consultant for RNA Protein Replacement Therapies | no data | no data | no data | |
Senior Vice President of Operations | no data | no data | no data | |
Senior Vice President of Immunotherapy & Preclinical Research | no data | no data | no data |
3.4yrs
Average Tenure
57yo
Average Age
Experienced Management: 0A3M's management team is considered experienced (3.4 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Supervisory Board Member | 2.5yrs | €90.00k | 0.00017% $ 49.6k | |
Independent Deputy Chairman Supervisory Board | 6.9yrs | €114.00k | no data | |
Independent Supervisory Board Member | 16.9yrs | €80.00k | no data | |
Independent Supervisory Board Chairman | 16.9yrs | €226.00k | 0.14% $ 40.5m | |
Member of Supervisory Board | 1.6yrs | €46.00k | no data | |
Supervisory Board Member | 2.5yrs | €105.00k | 0.00010% $ 29.2k |
4.7yrs
Average Tenure
58.5yo
Average Age
Experienced Board: 0A3M's board of directors are considered experienced (4.7 years average tenure).